Moleculin Biotech, a clinical-stage pharmaceutical company, announced a 1-for-20 reverse stock split of its common stock effective October 20, 2026. This move will reduce the number of outstanding shares from about 20.9 million to approximately 1.05 million, while the ticker symbol MBRX remains unchanged. The reverse split aims to consolidate shares without changing the par value and will include cash payments for fractional shares. The company continues to advance its pipeline, including its lead drug Annamycin in Phase 3 trials for treating acute myeloid leukemia and other cancers.
Moleculin Biotech's reverse stock split is the context for this health sector snapshot from Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 16, 2026 19:42 WIB: out of 150 priced US health-sector stocks, 96 rose and 43 fell. Immunovant Inc. (IMVT) traded at USD 27.98 with a 1-day increase of 1.69% and a typical hold time of 7 days, contrasting with Recursion Pharmaceuticals Inc. (RXRX) at USD 4.09, which declined by 1.56% and had a Pluang order activity of 41% sell versus 59% buy, held typically for 21 days. Roivant Sciences Ltd. (ROIV) was priced at USD 34.61, up 1.67%, with a typical hold time of 4 days.
Whole Lotta Dank, a Canadian cannabis brand platform, has launched its first brand, Dank Pack, debuting with Blueberry BBL available across Alberta. The company is expanding its portfolio with over 20 SKUs under regulatory review and is actively seek...
Nasdaq announced that trading in CN Healthy Food Tech Group Corp.'s common stock and warrants will resume on October 19, 2026, after being halted since October 1, 2025. The resumption marks the end of a year-long trading suspension, allowing investor...
David Solomon, CEO of Goldman Sachs, has been appointed as the new chair of The Business Council, taking over from Brian Cornell, Executive Chair of Target Corporation. This leadership change comes at a critical time as the Council addresses challeng...
The global pharmaceutical market is projected to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, expanding at a CAGR of 6.15%. Growth is fueled by advances in biologics, AI-driven drug discovery, specialty drugs, and manufacturing i...
SEDA Experts LLC has appointed Noor Ul Islam as Managing Director, enhancing its capabilities in risk management and securities practices. With nearly 30 years of experience at major financial institutions like Citibank and Barclays, Islam brings dee...
